Jela Theke Sarasari: All news live from the district
Source link
from https://www.thetimesofbengal.com/kolkata-updates/jela-theke-sarasari-all-news-live-from-the-district/
via The Times of Bengal | An exclusive 24*7 daily news portal RSS Feed
Jela Theke Sarasari: All news live from the district
Source link
Conference call begins at 4:00 p.m. Central time today
EDINA, MN, June 29, 2022 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (Nasdaq: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for its fiscal year ended March 31, 2022.
Key highlights for our fiscal year ended March 31, 2022, were:
Management Commentary
“The most significant event on our financial results during the fiscal year ended March 31, 2022, was our generation of over $100,000 in revenues from the commercialization and sale of our primary product, Spryng, to veterinary clinics.” Said John Lai, Chief Executive Officer of PetVivo.
“We continue to use the proceeds from our initial public offering to expand our sales and marketing efforts to generate clinical data to gain vet acceptance and generate increased revenue from the sale of Spryng”.
Fiscal Year Ended March 31, 2022 (“fiscal 2022”) Compared to The Year Ended March 31, 2021 (“fiscal 2021”)
Total Revenues. Revenues increased to $115,586 in fiscal 2022 compared to $12,578 in fiscal 2021 and consisted of sales to veterinary clinics. The Company began commercialization of its Spryng product in September 2021.
Total Cost of Sales. Cost of sales was $201,154 in fiscal 2022 compared to $10,695 for fiscal 2021. The increase is directly related to increased sales of the Spryng product. Cost of sales includes product costs related to the sale of products and labor and overhead costs. The increase and the negative gross margin are primarily attributed to our product costs and related product launch expenses from the commercialization of Spryng in September 2021.
Operating Expenses. Operating expenses increased to $4,970,960 in fiscal 2022 compared to $1,960,871 in fiscal 2021. Operating expenses consisted of general and administrative, sales and marketing, and research and development expenses. The increase is primarily due to increased G&A expenses and sales and marketing expenses related to the sale of our Spryng product.
General and administrative (“G&A”) expenses were $3,148,494 and $1,767,664 in fiscal 2022 and 2021, respectively. General and administrative expenses include compensation and benefits, contracted services, consulting fees, stock compensation and incremental public company costs.
Sales and marketing expenses were $1,347,585 and $94,997 in fiscal 2022 and 2021, respectively. Sales and marketing expenses include compensation, consulting, tradeshows, and stock compensation costs to support the launch of our Spryng product.
Research and development (“R&D”) expenses were $474,881 and $98,230 in fiscal 2022 and 2021, respectively. The increase was related to clinical studies and efforts to support the launch of Spryng.
Operating Loss. As a result of the foregoing, the Company’s operating loss was $5,056,528 and $1,958,988 in fiscal 2022 and 2021, respectively. The increase was related to the costs to support the launch of Spryng and the incremental public company costs.
Other Income (Expense). Other income was $41,533 in fiscal 2022 as compared to expense of $1,563,792 in fiscal 2021. Other income in fiscal 2022 consisted of the forgiveness of PPP Loan of $31,680 and net interest income of $9,853. Other expense in fiscal 2021 consisted primarily of derivative expense related to debt financing of $1,702,100 and interest expense of $228,595 partially offset by a gain on debt extinguishment of $366,903.
Net Loss. The Company’s net loss in fiscal 2022 was $5,014,995 or ($0.57) as compared to a net loss of $3,522,780 or ($0.57) per share in fiscal 2021. The weighted average number of shares outstanding was 8,760,877 compared to 6,198,717 for fiscal 2022 and 2021, respectively.
Balance Sheet and Inventory
At March 31, 2022, the Company had $6.1 million in cash and working capital of $5.6 million. The Company increased its inventory to $98,000 as of March 31, 2022 in order to support its expected revenue growth in 2023.
Business Update
In the first quarter of fiscal 2023, the Company entered into a Distribution Services Agreement with MWI Veterinarian Supply Co., a pre-eminent national distributor of veterinarian products (“MWI”). Pursuant to this agreement, we appointed MWI to distribute, advertise, promote, market, supply and sell our lead product, Spryng and other products on an exclusive basis for two (2) years within the United States.
Conference Call and Webcast
A live webcast of the conference call and related earnings release materials can be accessed on PetVivo’s Investor Relations website at:
https://audience.mysequire.com/webinar-view?webinar_id=4247f378-9329-46f0-adcf-44720e7f5ae6
A replay of the webcast will be available through the same link following the conference call. Participants can also access the call using the dial-in details below:
Date: Wednesday, June 29th, 2022
Time: 4:00 p.m CT (5:00 pm ET)
Dial-in: +1-346-248-7799
Meeting ID: 97245185036
Passcode: 740720
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc. is an emerging biomedical device company currently focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The Company’s strategy is to leverage human therapies for the treatment of dogs and horses in a capital and time-efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which entered the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company’s biomaterials, products, production processes, and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered intraarticular injection for the management of lameness and joint afflictions, such as osteoarthritis, in dogs and horses, is scheduled for expanded commercial sale in the fourth quarter of this year.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information, and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Contact:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
PETVIVO HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
March 31, 2022 | March 31, 2021 | |||||||
Current Assets | ||||||||
Cash and cash equivalents | $ | 6,106,827 | $ | 23,578 | ||||
Accounts receivable | 2,596 | – | ||||||
Inventory, net | 98,313 | – | ||||||
Prepaid expenses and other assets | 547,664 | 123,575 | ||||||
Total Current Assets | 6,755,400 | 147,153 | ||||||
Property and Equipment, net | 311,549 | 214,038 | ||||||
Other Assets: | ||||||||
Deferred offering costs | – | 280,163 | ||||||
Operating lease right-of-use asset | 299,101 | 157,760 | ||||||
Patents and trademarks, net | 48,452 | 27,932 | ||||||
Security deposits | 12,830 | 8,201 | ||||||
Total Other Assets | 360,383 | 474,056 | ||||||
Total Assets | $ | 7,427,332 | $ | 835,247 | ||||
Liabilities and Stockholders’ Equity (Deficit) | ||||||||
Current Liabilities | ||||||||
Accounts payable | $ | 323,384 | $ | 408,873 | ||||
Accrued expenses | 784,375 | 554,012 | ||||||
Convertible notes and accrued interest | – | 235,671 | ||||||
Accrued expenses – related parties | – | 36,808 | ||||||
Operating lease liability – current portion | 59,178 | 26,582 | ||||||
PPP Loan and accrued interest | – | 39,020 | ||||||
Notes payable and accrued interest – directors | – | 20,000 | ||||||
Notes payable and accrued interest – related party | – | 44,554 | ||||||
Note payable and accrued interest (current portion) | 6,549 | 39,528 | ||||||
Total Current Liabilities | 1,173,486 | 1,405,048 | ||||||
Other Liabilities | ||||||||
Note payable and accrued interest (net of current portion) | 27,201 | – | ||||||
Operating lease liability (net of current portion) | 239,923 | 131,178 | ||||||
Share-settled debt obligation – related party, net of debt discount | – | 196,000 | ||||||
Total Other Liabilities | 267,124 | 327,178 | ||||||
Total Liabilities | 1,440,610 | 1,732,226 | ||||||
Commitments and Contingencies (see Note 13) | ||||||||
Stockholders’ Equity (Deficit): | ||||||||
Preferred stock, par value $0.001, 20,000,000 shares authorized, issued 0 and 0 shares outstanding at March 31, 2022 and March 31, 2021 | – | – | ||||||
Common stock, par value $0.001, 250,000,000 shares authorized, issued 9,988,361 and 6,799,113 shares outstanding at March 31, 2022 and March 31, 2021, respectively | 9,988 | 6,799 | ||||||
Additional Paid-In Capital | 69,103,155 | 57,207,648 | ||||||
Accumulated Deficit | (63,126,421 | ) | (58,111,426 | ) | ||||
Total Stockholders’ Equity (Deficit) | 5,986,722 | (896,979 | ) | |||||
Total Liabilities and Stockholders’ Equity (Deficit) | $ | 7,427,332 | $ | 835,247 |
The accompanying notes are an integral part of these audited consolidated financial statements.
PETVIVO HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Year Ended March 31, |
||||||||
2022 | 2021 | |||||||
Revenues | $ | 115,586 | $ | 12,578 | ||||
Cost of Sales | 201,154 | 10,695 | ||||||
Gross Profit (Loss) | (85,568 | ) | 1,883 | |||||
Operating Expenses: | ||||||||
Sales and Marketing | 1,347,585 | 94,977 | ||||||
Research and Development | 474,881 | 98,230 | ||||||
General and Administrative | 3,148,494 | 1,767,664 | ||||||
Total Operating Expenses | 4,970,960 | 1,960,871 | ||||||
Operating Loss | (5,056,528 | ) | (1,958,988 | ) | ||||
Other Income (Expense) | ||||||||
Gain on Debt Extinguishment | – | 366,903 | ||||||
Forgiveness of PPP loan and accrued interest | 31,680 | – | ||||||
Derivative Expense | – | (1,702,100 | ) | |||||
Interest Income (Expense) | 9,853 | (228,595 | ) | |||||
Total Other Income (Expense) | 41,533 | (1,563,792 | ) | |||||
Net Loss before taxes | (5,014,995 | ) | (3,522,780 | ) | ||||
Income Tax Provision | – | – | ||||||
Net Loss | $ | (5,014,995 | ) | $ | (3,522,780 | ) | ||
Net Loss Per Share: | ||||||||
Basic and Diluted | $ | (0.57 | ) | $ | (0.57 | ) | ||
Weighted Average Common Shares Outstanding: | ||||||||
Basic and Diluted | 8,760,877 | 6,198,717 |
The accompanying notes are an integral part of these audited consolidated financial statements.
Shares retroactively restated for 1-for-4 reverse stock split in December of 2020.
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.
The post PetVivo to Discuss Financial Results for the Fiscal Year End ended March 31, 2022 and Business Update appeared first on DKODING.
New York, NY, June 29, 2022 (GLOBE NEWSWIRE) — E.Merge Technology Acquisition Corp. (the “Company”) announced today that the company’s Board of Directors (the “Board”) has approved an increase in the size of the Board from five (5) directors to seven (7) directors and elected Benjamin Reitzes and Morgan Hermand as members of the Board. The Board determined that each of Benjamin Reitzes and Morgan Hermand is an “independent director” as defined in the Nasdaq listing standards and applicable rules of the Securities and Exchange Commission.
The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on companies in the software and internet technology industries. The Company is led by Chairman, S. Steven Singh, and Co-Chief Executive Officers, Jeff Clarke and Guy Gecht.
FORWARD-LOOKING STATEMENTS
This press release may contain statements that constitute “forward-looking statements,” including with respect to the initial public offering. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact
Jeff Clarke
Guy Gecht
E.Merge Technology Acquisition Corp.
(619) 736-6855
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.
The post E.Merge Technology Acquisition Corp. Announces Appointment of Benjamin Reitzes and Morgan Hermand to Board of Directors appeared first on DKODING.
TORONTO, June 29, 2022 (GLOBE NEWSWIRE) — Ninepoint Partners LP (“Ninepoint”) is pleased to announce that the ETF series units of Ninepoint Target Income Fund (the “Fund”) will be available for purchase in Canadian dollars (Ticker: TIF) on the NEO Exchange as of the open of trading on June 30, 2022.
Supported by RBC Quantitative Investment Solutions, the Fund leverages RBC Capital Markets’ diversified, systematic put selling strategies on multiple equity indices seeking to deliver a 6% target income distribution.*
Fund Objective
The Ninepoint Target Income Fund seeks to provide unitholders with stable, monthly distributions and lower volatility than a direct investment in the broad equity markets by investing primarily in a diversified portfolio of equity index based investments that generates income and using derivatives strategies to moderate the market volatility of those investments.
About Ninepoint Partners
Based in Toronto, Ninepoint Partners is one of Canada’s leading alternative investment management firms overseeing over $8 billion in assets under management and institutional contracts. Committed to helping investors explore innovative investment solutions that have the potential to enhance returns and manage portfolio risk, Ninepoint offers a diverse set of alternative strategies spanning Equities, Fixed Income, Alternative Income, Real Assets, F/X and Digital Assets.
For more information on Ninepoint, please visit www.ninepoint.com or inquiries regarding the Offering, please contact us at (416) 943-6707 or (866) 299-9906 or invest@ninepoint.com.For more information on Ninepoint, please visit www.ninepoint.com or inquiries regarding the Offering, please contact us at (416) 943-6707 or (866) 299-9906 or invest@ninepoint.com.
Media Inquiries:
Joanne Kearney
Smithcom Ltd.
416.804.5949
joanne.kearney@smithcom.ca
Sales Inquiries:
Neil Ross
Ninepoint Partners
416.945.6227
nross@ninepoint.com
* The monthly distribution amount may be adjusted by Ninepoint without notice throughout the year as market conditions change. Monthly distributions will be comprised of net income, net realized capital gains and/or return of capital. Any net income and/or net realized capital gains earned by the Fund in excess of the monthly distribution will be distributed to unitholders annually in December.
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.
The post Ninepoint Launches Target Income Fund appeared first on DKODING.
By: Mahiyan Chakrabarti
Assam and parts of North East India and Bangladesh are gripped with the onslaught of floods that have claimed many lives and displaced millions. Google have launched a combination of Crisis Response efforts to help reach critical support to impacted people and communities.
As part of this effort, Google.org has also made a grant of $500,000 to the Center for Disaster Philanthropy to support community-based organizations working to provide emergency support and long-term recovery in the affected areas. This includes supporting organizations restoring household food security through dry ration, direct cash assistance, and distribution of hygiene kits.
In addition, Google has also launched a campaign for Googlers to donate, matched 100% by Google.
For those looking for relevant information on the flood situation, they have launched the SOS alert for Assam floods bringing together updates from authoritative local and national sources to the top of Search results. If one is close to the affected areas, this Search will bring up emergency phone numbers, websites, and maps. If one is outside of the affected area, the Search will also show an SOS Alert that provides a timely overview of the situation.
To make it easy for people looking to donate funds towards flood relief efforts in Assam, Spots for Smile Foundation and Goonj are now live on Google Pay. Google will continue to add more organizations who are running fundraising efforts for flood relief, which undoubtedly will help those who are really effected and needs urgent relief.
By – Rahul Kuila
The brand new music video ‘Cholo Paltai’ has been released under the banner of KSS Music India. KSS Productions and Entertainment is already very well known in the world of Bengali entertainment, with releases such as ‘8/12’ (Binay Badal Dinesh), followed by ‘Mrityupathojatri’ and finally ‘Shrimati’, which will be KSS’s latest release.
KSS Production and Entertainment, helmed by Kan Singh Sodha, while presenting good and meaningful films to the film goers of Bengal, have also been creating and releasing music videos and short films as well throughout the year from their two virtual platforms KSS the Originals and KSS Music India. Their brand new music video ‘Cholo Paltai’ has just been released. With this music video, KSS Music India seeks to create a unique common world for all by removing any and all differences in our surroundings that stop us from being one.
‘Cholo Paltai’ conveys a simple message for people to unite in current times where in religious, social and economic gapsa are widening ruthlessly and racism is increasing drastically in our society day by day. The song is sung by Kajal Chatterjee, Abir Biswas, Rupak Tiary and Rishi Panda. Sayan Samrat has composed the song, Samrat Debnath has written the lyrics, Priyanshu Kaushik has played the violin, Kuntal Dey has performed on the guitar and done the mixing and mastering of the song.
As you will witness in this video, several new singers are seen performing the song ‘Cholo Paltai’ together. The video is directed by Arpa, camerawork by Shaan Chakraborty and the edit by Aritra.
This song ‘Cholo Paltai’ is a little different one from other songs released on KSS Music India. We live in times when the issue of harmony is mercilessly stares at our faces. The way the whole world is war-torn at the moment, the way people are becoming accustomed to looking at each other with suspicion, a gentle touch of harmony can save the world from further decline. Based on this very thought, I sincerely hope that this endeavour of ours will call for true change and upliftment in society. This song has the potential to become the anthem of the new generation as well.”
–Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy–
–Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sales, as well as development, commercial, and sales-based milestone payments–
-Approval by MHRA follows the European Commission’s marketing authorization, granted in June 2022-
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – June 28, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Yselty® (linzagolix), an oral GnRH antagonist, for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age. Yselty® is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.
The MHRA approval follows the granting of marketing authorization by the European Commission earlier in June 2022.
Yselty® offers a potentially best-in-class efficacy rate 1,2,3 and favorable tolerability profile for women with UF for whom hormonal add-back therapy (ABT, estradiol 1 mg and norethisterone acetate 0.5 mg) is appropriate. For women with UF who cannot or do not want to take hormones, Yselty® is the first and only approved oral GnRH antagonist with a non-hormonal dosing option.
“We are pleased to announce our second regulatory approval for Yselty®. As the first and only approved GnRH antagonist to offer flexible dosing options with and without additional hormonal therapy, we hope to redefine care for women suffering from uterine fibroids. We are excited to commercialize Yselty® in Great Britain and advance medical options for women suffering from this chronic and debilitating disease with our partner Theramex, a global leader in women’s health,” said Brian O’Callaghan, CEO of ObsEva.
Consistent with the EU approval, Yselty® is approved in Great Britain at the following doses:
In February 2022, ObsEva entered into a strategic licensing agreement with Theramex to support the commercialization and market introduction of linzagolix across international markets outside of the U.S., Canada, and Asia.
The NDA for linzagolix in the U.S. is currently under review by the FDA, with a PDUFA target action date of September 13, 2022.
About Yselty® (linzagolix)
Linzagolix is a novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile 1,2,3. Linzagolix was developed to offer flexible dosing options with and without hormonal add-back therapy to women suffering from uterine fibroids, and is approved in the EU and Great Britain. For women with uterine fibroids for whom hormonal add-back therapy is appropriate, linzagolix has the potential to offer a best-in-class efficacy rate and favorable tolerability profile. For women with uterine fibroids who cannot or do not want to take hormones, linzagolix is the first and only approved oral GnRH antagonist with a non-hormonal dosing option in the EU and Great Britain. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product. Linzagolix is currently under review by the FDA, with a PDUFA target action date of September 13, 2022.
About Uterine Fibroids
Uterine fibroids are common benign tumors of the muscular tissue of the uterus which affect women of childbearing age and can vary in size from undetectable to large bulky masses. Few long-term medical treatments are available, and as a result, approximately 300,000 hysterectomies are performed for uterine fibroids every year in the United States.
The symptoms of uterine fibroids are wide-ranging and include heavy menstrual bleeding, anemia, pelvic pressure and bloating, urinary frequency and pain that can be extremely debilitating with a significant impact on quality of life. These symptoms can also have an impact on mental health, creating the additional burden of anxiety and distress.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. The Company’s first, just recently approved drug is Yselty® (linzagolix), a once daily, oral GnRH receptor antagonist that was developed to offer flexible dosing options to women suffering from uterine fibroids, and is approved in the EU and Great Britain. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. Theramex supports women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Theramex’s commitment is to listen to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex’s vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.
About Kissei
Linzagolix has been discovered by Central Research Laboratories of Kissei Pharmaceutical Co., Ltd. Kissei is a Japanese pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide in the focus fields of urology, nephrology/dialysis, gynecology and rare/intractable diseases.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “might”, “ongoing”, “objective”, “plan”, “potential”, “predict”, “should”, “will”, “would”, or the negative of these and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential approval of linzagolix by the FDA, and the timing of such approval, the timing or results of interactions with regulatory authorities, clinical development of ObsEva’s product candidates, including the timing, advancement of, and potential therapeutic benefits of such product candidates, including linzagolix, the potential for linzagolix and other product candidates to be commercially competitive, expectations regarding commercial launch of linzagolix, the success of the Company’s partnerships with third parties and the amount of potential payments the Company may earn pursuant to such partnerships, including with Theramex, expectations regarding regulatory and development milestones and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, including interactions with the FDA during the New Drug Application process for linzagolix, ObsEva’s reliance on third parties over which it may not always have full control, and the capabilities of such third parties, the impact of the ongoing novel coronavirus outbreak and other geopolitical events, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with Securities and Exchange Commission (SEC) on March 10, 2022, in the Report on Form 6-K filed with the SEC on May 17, 2022 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and, except as required by law, ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
CEO Office contact
Shauna Dillon
shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Katja Buhrer
katja.buhrer@obseva.com
+1 (917) 969-3438
1. Stewart E, ASRM 2020; Late-breaker abstract P-930
2. Al-Hendy A, NEJM 2021; 384:630-42
3. Schlaff W, NEJM 2020; 382:328-40
Attachment
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.
The post ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids appeared first on DKODING.
By – Rahul Kuila
SVF in association with the cultural centre of Kolkata, Nandan, launched the trailer of its upcoming venture ‘Kuler Achaar’ which is slated to release in theatres on 15th July 2022. Kuler Achaar is a tumultuous joyful ride that tells a story revolving around the willingness of a lady to keep her maiden surname and the comedic yet poignant complexities that revolve around the idea.
The film is a family drama, written & directed by Sudeep Das. This is his first collaboration with SVF. The very talented Mainak Bhaumik joins the crew to take the position of creative director ‘Kuler Achaar’. The music of the film is composed by the top-notch ‘Prosen Er Dol Bol’ and the background music is done by Savvy. The ensemble cast includes Indrani Halder, Neel Mukherjee, Madhumita Sarcar and Vikram Chatterjee. Madhumita will be back on the screen for ‘Kuler Achaar’ after the huge success of ‘Cheeni’ and ‘Tangra Blues’, Vikram Chatterjee who has already stolen people’s heart through his excellent performance in different TV serials and web series, comes back to big screen as the male lead in Kuler Achaar. He will be seen playing the role of Pritam – Mithi’s supportive and liberal husband.
Indrani Haldar will be back on the big screen after a hiatus of almost five years. She will be seen playing Madhumita’s mother-in-law, a character that holds an extremely strong position in Mithi’s life. Indrani Haldar, who has unequivocally made a mark in playing the role of the quintessential Indian mother in TV content, is now here to steal the show yet again with Kuler Achaar. Neel Mukherjee, on the other hand, will be seen playing the role of Mithi’s father-in-law.
“It feels great to be back after such a long gap. The message of the film is extremely insightful, every woman will relate to it and find relevance of it at any situation in their life. The film is crafted with love, emotions and I shall keep it for the audience to find our journey on 15th July” – said Indrani Halder who will be seen in the role of Mitali.
Both Vikram Chatterjee & Madhumita Sarcar who have already become a popular on-screen jodi after the first song release of the same film- Bhul Korechey Bhul, said, “We are extremely thrilled and elated to be a part of this wonderful project. The first song of the film has already garnered a huge response and we really hope that our film is also appreciated. Really looking forward to it.”
Watch the trailer – http://bit.ly/KulerAchaarTrailer_SVF
CHICAGO, June 28, 2022 (GLOBE NEWSWIRE) — Nerdio today announced it has been named a finalist of the Commercial Marketplace 2022 Microsoft Partner of the Year Award. The company was honored among a global field of top Microsoft partners for demonstrating excellence in innovation and implementation of customer solutions based on Microsoft technology.
“I know how challenging it is to earn the Partner of the Year finalist distinction and stand out among thousands of global partners vying for the accomplishment,” said Nerdio Board of Directors’ member and former Microsoft Global Channel Chief Gavriella Schuster. “To see Nerdio recognized in this manner speaks loudly to the incredible value they deliver on top of Azure Virtual Desktop and Windows 365, and to partners and organizations worldwide.”
The Microsoft Partner of the Year Awards recognize Microsoft partners that have developed and delivered outstanding Microsoft-based applications, services and devices during the past year. Awards were classified in various categories, with honorees chosen from a set of more than 3,900 submitted nominations from more than 100 countries worldwide. Nerdio was recognized for providing outstanding solutions and services in the Commercial Marketplace category.
The Commercial Marketplace Partner of the Year Award recognizes a partner organization that excels at providing innovative and unique solutions via Microsoft’s commercial marketplace – either Microsoft AppSource or Azure Marketplace. In Nerdio’s case, both Nerdio Manager for Enterprise and Nerdio Manager for MSP can be installed directly from the Azure Marketplace.
“I am honored to announce the winners and finalists of the 2022 Microsoft Partner of the Year Awards,” said Nick Parker, corporate vice president of Global Partner Solutions at Microsoft. “These partners were outstanding among the exceptional pool of nominees and I’m continuously impressed by their innovative use of Microsoft Cloud technologies and the impact for their customers.”
Microsoft Partner of the Year Awards are announced annually prior to the company’s global partner conference, Microsoft Inspire, which will take place on July 19-20 this year. Additional details on the 2022 awards are available on the Microsoft Partner Network blog: https://blogs.partner.microsoft.com/mpn/congratulations-to-the-2022-microsoft-partner-of-the-year-awards-winners-and-finalists/. The complete list of categories, winners and finalists can be found at https://partner.microsoft.com/en-us/inspire/awards.
About Nerdio
Nerdio empowers Managed Service Providers (MSPs) and enterprises to build successful cloud practices in Microsoft Azure with Azure Virtual Desktop and Windows 365. Nerdio Manager for Enterprise is a packaged Azure application that runs in users’ own tenant without compromising security and compliance by allowing third-party vendors access into the IT environment. Nerdio Manager for MSP empowers MSPs to deploy, manage, and optimize virtual desktop environments in Microsoft Azure through easy multi-tenant management. For more information, please visit www.getnerdio.com.
CONTACT: Haley Sullivan Nerdio 2243690112 hsullivan@getnerdio.com
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.
The post Nerdio Recognized as Finalist of 2022 Microsoft Commercial Marketplace Partner of the Year appeared first on DKODING.
Jela Theke Sarasari: See all the news directly from different districts of the state at a glance
Source link
MONTREAL, June 28, 2022 /PRNewswire/ — World Design Organization (WDO)® announced today that internationally renowned designer and gerontologist Dr. Patricia Moore has been named as the recipient of the 2022 World Design Medal for her significant contributions to the advancement of the industrial design profession.
As a pioneering figure in design, Dr. Patricia Moore is a leading authority on consumer lifespan behaviours and requirements. For a period of three years from 1979 to 1982, Moore travelled throughout the United States and Canada disguised as women of more than 80 years of age. This experience of responding to people, products, and environments as an elder enabled an empathetic approach to design that informed much of her future work, from NASA to Whirlpool.
“Patricia represents an inspiration to many, and her decades-long career stands a testament to her commitment to accessible and inclusive design,” stated WDO President David Kusuma. “WDO is honoured to take this opportunity to recognize her leadership, creativity and intellect that to this day, continues to have a profound impact on the industrial design landscape and the designers of tomorrow.”
Following a public call for nominations, Moore was selected from among a list of nominees representing 11 countries around the world by the World Design Medal Selection Committee. The committee, composed of members of the WDO and Board of Directors and Senators, acknowledged Moore’s many years of dedicated service and her impact on the design community as a whole.
“To live life with the blessing of a creative career is a joy that defies description, but to have the support of the family that is the WDO is the greatest gift of all,” stated Patricia Moore. “I have no doubt that as we emerge from a crippling global pandemic, the WDO will provide for systematic dignity, equity and recovery with the leadership that can only be achieved by Design.”
The official World Design Medal presentation will take place on 29 June 2022 on the occasion of World Industrial Design Day, during WDO’s 24-hour virtual event let’s talk: leadership. Moore will join the programme to share her insight on the topic of design leadership as part of a 30-minute session moderated by WDO President, David Kusuma. To register for this special event, please visit: https://hopin.com/events/world-industrial-design-day-2022.
More information on the World Design Medal can be found by visiting https://wdo.org/programmes/world-design-medal/.
About World Design Organization
World Design Organization (WDO)® is an international non-governmental organization and the international voice for industrial design. We advocate for Design for a Better World, promoting and sharing knowledge of industrial design-driven innovation that enhances the economic, social, cultural, and environmental quality of life. Today, WDO services over 185 member organizations, representing thousands of industrial designers around the world.
About World Design Medal
The World Design Medal was established in 2017 on the occasion of WDO’s 60th anniversary to honour an individual who has made a significant contribution to the advancement of the industrial design profession. The award recognizes the impact one designer has had on their peers, in their local design community and internationally.
Media contact: Natalie Dutil, WDO Communications Manager, natalie@wdo.org
The content is by PR NewsWire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.
The post WDO names Patricia Moore as recipient of 2022 World Design Medal™ appeared first on DKODING.
The 5th edition of the Charles Correa Memorial Lecture was held on 25th June, 2022, in the presence of distinguished guests and delegates at AltAir, Ecocentre, 19th Floor, EM Block, Sector V, Salt Lake. Started in 2016, the event marks the death anniversary of the master architect of post-Independent India and is held annually in his honour.
The Lectures were delivered by two eminent architects, Mr C. Anjalendran from Colombo, Sri Lanka, and Professor K.T Ravindran from New Delhi, India.
C. Anjalendran, is a celebrated Sri Lankan architect known for producing architecture that is a living embodiment of his unbiased and free thinking, inclinations to nature, and to the local idioms and cultural diaspora. His transcendence into Utilitarian Architecture, with an aesthetic appeal, has been hailed as revolutionary by his peers. His work has been exhibited worldwide and he has been decorated with several awards and citations, including the Golden Award for Global Contribution to Architecture in 2011.
Professor KT Ravindran is a stalwart of the industry. Popularly known as KT among his peers, contemporaries, students, and admirers in India and beyond, he is an urban designer involved with several national and international institutions in various capacities. From being the Chairman of the Architectural Heritage Advisory Committee of INTACH, to being a member of the Advisory Board for the United Nations Capital Master Plan, New York, Professor Ravindran has held numerous such distinguished posts.
Speaking on the occasion, Mr. Harshavardhan Neotia, Chairman, Ambuja Neotia Group said, “Charles Correa was ahead of his times. He had planned and designed City Centre Salt Lake many years ago inspired by the Indian open-space market. Today, when architects across the globe are focusing on this open-space design in the wake of the pandemic in 2020, City Centre not only has stayed relevant all through but also leads by example in terms of futuristic and functional design for a modern mall. That’s the hallmark of the architect visionary.”
Speaking on the occasion, Mr. Ashish Acharjee, architect and Principal Organiser of the ‘Annual Charles Correa Memorial Lecture’ said…The Memorial Lecture supported by the Ambuja Neotia Group and the Charles Correa Foundation is a homage to the architectural brilliance of the legend.
Ad hoc announcement pursuant to Art. 53 LR
Pratteln, Switzerland, June 27, 2022 — Santhera Pharmaceuticals (SIX: SANN) announces that Chairman of the Board Elmar Schnee will not stand for re-election at the upcoming Annual General Meeting on June 30, 2022. The Board of Directors has unanimously nominated Thomas Meier, PhD, for election as Chairman of the Board and as member of the Compensation Committee.
Elmar Schnee, Chairman of the Board and member of the Compensation Committee of Santhera since 2017, will not stand for re-election and will step down from Santhera’s Board of Directors as of June 30, 2022. The Board of Directors expresses its sincerest gratitude to Mr. Schnee for his valued leadership over the past, challenging years.
The Board of Directors of Santhera has unanimously nominated Thomas Meier, PhD, for election as Chairman of the Board and as member of the Compensation Committee. Thomas Meier, PhD, was CEO of Santhera from October 2011 to November 2019 and has been a director of the Company since 2017.
The Board of Directors seeks to nominate one or more additional members of the Board of Directors at a later stage.
The updated proposals of the Board of Directors to the Annual General Meeting of June 30, 2022 can be downloaded at https://www.santhera.com/share-bondholder-meetings. Shareholders eligible to vote may grant powers of attorney and give instructions to the independent proxy or change instructions that had been electronically given until June 28, 2022, 11.59 pm (CEST). Unless other instructions are given to the independent proxy, the independent proxy, in accordance with the proxy form or electronic instruction form, is appointed to vote for the proposals made by the Board of Directors, including the amendments announced today.
Corporate calendar
June 30, 2022 Annual General Meeting
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The Company plans to complete the rolling submission of its filing for approval for vamorolone with the U.S. FDA in June 2022. The clinical stage pipeline also includes lonodelestat to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases. Santhera out-licensed rights to its first approved product, Raxone® (idebenone), outside North America and France for the treatment of Leber’s hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com.
Raxone® is a trademark of Santhera Pharmaceuticals.
For further information please contract:
public-relations@santhera.com or
Eva Kalias, Head Investor Relations & Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
# # #
Attachment
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.
The post Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board appeared first on DKODING.
https://ift.tt/AT2K8gG Home Lifestyle Curry Leaves Benefits: 5 Ways to Use Kadh…